Savient Pharmaceuticals (SVNT) Posts Q3 Loss of 56c/Share

Savient Pharmaceuticals (NASDAQ: SVNT) reported Q3 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $5.85 million.

For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c